St. Antonius Ziekenhuis

Running trials

• Not yet recruiting

  Spontaneous Coronary Artery Dissection - AntipLatelet Therapy Intensity in Guided coNservative Management (SCAD-ALIGN) Trial

  NCT07683923· Phase 4· Universitätsklinikum Hamburg-Eppendorf· Source

• Not yet recruiting

  Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis

  NCT07441408· Phase 3· Bristol-Myers Squibb· Source

• Not yet recruiting

  A Phase 2 trial of AGMB-447 in participants with idiopathic pulmonary fibrosis

  2026-526404-71-00· Phase 2· Agomab Spain S.L.U.· Source

• Not yet recruiting

  Addition of ritonavir to ibrutinib treatment in patients with chronic leukemia and certain types of lymphoma

  2026-526101-15-00· Phase 2· Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting· Source

• Active, not recruiting

  Investigating the Impact of Nudging Cardiologists to Prescribe Class I Recommendations Foundational- and Additional Medical Therapy in Heart Failure Patients

  NCT06844006· Medisch Spectrum Twente· Source

• Not yet recruiting

  Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma With Pirtobrutinib in Combination With Epcoritamab if the Disease Comes Back After Previous Treatment.

  NCT07860775· Phase 2· Stichting Hemato-Oncologie voor Volwassenen Nederland· Source

• Recruiting

  A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D–Mutated Metastatic Pancreatic Ductal Adenocarcinoma (DAWN-303)

  2025-525009-18-00· Phase 3· Incyte Corp.· Source

• Recruiting

  HO182 CLL: Treatment of patients with chronic lymphocytic leukemia (CLL) with 6 cycles of rituximab in combination with 6 or 26 cycles of venetoclax upon recurrence of the disease after previous treatment

  2025-524283-38-00· Phase 3· Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting· Source

• Not yet recruiting

  Endoscopic (EID) Versus Surgical (TAMIS) Local Excision for Early Stage Rectal Cancer

  NCT07846046· Amsterdam UMC, location VUmc· Source

• Recruiting

  Parasternal Extravascular ICD System Pivotal Clinical Investigation (ALARION EV) Study

  NCT07324031· AtaCor Medical, Inc.· Source

• Recruiting

  Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone in Adults With Idiopathic Pulmonary Fibrosis (IPF)

  NCT07284602· Phase 3· PureTech· Source

• Not yet recruiting

  PREOPANC-6 study: dendritic cell immunotherapy after FOLFIRINOX chemotherapy in patients with resectable pancreatic cancer

  2025-523134-28-00· Phase 2/3· Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)· Source

• Recruiting

  A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

  NCT07567001· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  The SELEQT-HF (SELEnium and CoQ10 NuTrition for Heart Failure) Study Will Evaluate the Effect of Adding Selenium/and coQ10 on Top of Standard HF Therapy in Patients With HF and Will do so Using a Pragmatic, Registry Based Randomized Controlled Trial in the Netherlands.

  NCT07234422· Phase 3· Netherlands Heart Institute· Source

• Recruiting

  Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

  NCT07491445· Phase 3· Revolution Medicines, Inc.· Source

• Recruiting

  A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

  NCT07258511· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Non-Invasive Detection of Pulmonary Right-to-Left Shunts Using the SONAS Ultrasound Device

  NCT07414446· St. Antonius Hospital· Source

• Recruiting

  Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab.

  NCT07107529· Phase 2· European Myeloma Network B.V.· Source

• Active, not recruiting

  BaLloon-based PFA Ablation poST Approval Outcomes for PAF and PersAF

  NCT07181590· Abbott Medical Devices· Source

• Recruiting

  NO Re-excision MelanomA - NORMA 2

  NCT07530887· Phase 3· Marieke Goodijk· Source

• Recruiting

  Optimized Expansion of the Implanted Transcatheter Aortic Valve

  NCT07042529· Ole De Backer· Source

• Recruiting

  A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

  NCT07144280· Phase 3· Pfizer· Source

• Recruiting

  A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)

  2024-513613-12-00· Phase 1/2· Novartis Pharma AG· Source

• Recruiting

  Coherent Sine Burst Electroporation (CSE) Ablation System US IDE Study for Patients With Atrial Fibrillation

  NCT06784466· Arga Medtech SA· Source

• Recruiting

  Preventing postoperative complications in patients undergoing high-risk pancreatoduodenectomy with a bundle approach including hydrocortisone, ocreotide, and teres ligament patch (PANENCA): an international randomized controlled multicenter trial

  2024-519667-18-00· Phase 4· Amsterdam UMC Stichting· Source

• Recruiting

  Prospective Data Collection Initiative on Thoracic Malignancies

  NCT06996249· Dutch Society of Physicians for Pulmonology and Tuberculosis· Source

• Recruiting

  A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

  NCT07062965· Phase 3· Pfizer· Source

• Recruiting

  This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

  NCT06758401· Phase 3· Pfizer· Source

• Recruiting

  Study of Sacituzumab Govitecan Versus Standard of Care in Participants with Previously Treated Extensive Stage Small Cell Lung Cancer

  2024-515884-69-00· Phase 3· Gilead Sciences Inc.· Source

• Recruiting

  A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy

  NCT06963827· Phase 3· Takeda· Source

• Recruiting

  An Open-Label Extension Study of Subjects who Received an Avalyn Inhaled Antifibrotic Agent

  2024-518289-28-00· Phase 2· Avalyn Pharma Inc.· Source

• Active, not recruiting

  Deliver mOre aPplications for More Durable Pulmonary Vein IsOlation

  NCT07021313· R&D Cardiologie· Source

• Recruiting

  EURO-STIM Registry

  NCT06971796· Inspire Medical Systems, Inc.· Source

• Recruiting

  A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart

  NCT06935370· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  Sequential Imaging of Suspicion of Prostate Cancer Reducing Overdiagnosis and Unnecessary Biopsy With Timely Diagnosis of Significant Cancer

  NCT07180381· St. Antonius Hospital· Source

• Active, not recruiting

  WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

  NCT06967805· Phase 2· Mediar Therapeutics· Source

• Recruiting

  An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)

  NCT06951217· Phase 2· Avalyn Pharma Inc.· Source

• Recruiting

  OPTImaL:Optimisation of Treatment for Patients With Low Stage Triple-negative Breast Cancer With High Stromal Tumor-infiltrating Lymphocytes

  NCT06476119· The Netherlands Cancer Institute· Source

• Recruiting

  StAtins in Frail oldEr patients with ischemic Stroke or Transient ischemic attack – The Randomized Controlled Trial

  2024-517343-31-00· Phase 4· Amsterdam UMC Stichting· Source

• Recruiting

  Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

  NCT06890598· Phase 3· Eli Lilly and Company· Source

• Recruiting

  Safety and Efficacy of Intravenous Thrombolysis in Patients With Ischemic Stroke and Direct Oral Anticoagulants Intake

  NCT06571149· Phase 4· Insel Gruppe AG, University Hospital Bern· Source

• Recruiting

  A Prospective Randomised Study of Treatment Selection Based on Epigenetic Markers Versus Standard of Care Treatment Selection in Adults With CROHN's Disease

  NCT07363044· Alimentiv Inc.· Source

• Recruiting

  Ulipristal versus surgery for symptomatic uterine fibroids

  2024-512602-26-00· Phase 4· Amsterdam UMC Stichting· Source

• Recruiting

  inDividual, Targeted thrombosIS Prophylaxis Versus the Standard 'One Size Fits All' Approach in Patients Undergoing Total hIp or Total kNee replaCemenT

  NCT06581965· Phase 4· Leiden University Medical Center· Source

• Recruiting

  Timing of start of systemlc treatment for asymptomatic MEtastasized PANcreatic cancer (TIMEPAN): a prospective multicenter patient preference cohort

  NCT04897854· Phase 3· Amsterdam UMC· Source

• Recruiting

  DAROTAXEL

  2024-516939-28-00· Phase 2· Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)· Source

• Recruiting

  Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)

  NCT06496581· Phase 3· UNICANCER· Source

• Active, not recruiting

  A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

  NCT06508658· Phase 3· Genmab· Source

• Recruiting

  LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC

  NCT06216301· Phase 3· NovoCure GmbH· Source

• Recruiting

  CellFX® nsPFA™ Cardiac Surgery System to Treat Atrial Fibrillation

  NCT06355063· Pulse Biosciences, Inc.· Source

Showing 50 of 140.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Atrial fibrillation8 recruiting
• Lung cancer8 recruiting
• Aortic stenosis6 recruiting
• Heart failure6 recruiting
• Pancreatic cancer6 recruiting
• Prostate cancer6 recruiting
• Coronary artery disease5 recruiting
• Idiopathic pulmonary fibrosis5 recruiting
• Stroke5 recruiting
• Colorectal cancer4 recruiting
• Chronic lymphocytic leukaemia3 recruiting
• Multiple myeloma3 recruiting
• Barrett's oesophagus2 recruiting
• Bladder cancer2 recruiting
• High blood pressure2 recruiting
• Kidney cancer2 recruiting
• Obesity2 recruiting
• Aortic aneurysm1 recruiting
• Atopic dermatitis (eczema)1 recruiting
• Childhood cancers1 recruiting
• Crohn's disease1 recruiting
• Deep vein thrombosis and pulmonary embolism1 recruiting
• Gastric and oesophageal cancer1 recruiting
• Hodgkin lymphoma1 recruiting
• IgA nephropathy1 recruiting
• Liver cirrhosis1 recruiting
• Mantle cell lymphoma1 recruiting
• Melanoma1 recruiting
• Mesothelioma1 recruiting
• Metastatic breast cancer1 recruiting
• Multiple sclerosis1 recruiting
• Obstructive sleep apnoea1 recruiting
• Peripheral artery disease1 recruiting
• Pulmonary arterial hypertension1 recruiting
• Thymoma and thymic carcinoma1 recruiting
• Triple-negative breast cancer1 recruiting
• Uterine fibroids1 recruiting
• Ventricular tachycardia1 recruiting

Closed trials

• Recruiting

  A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

  NCT07221357· Phase 2/3· Bristol-Myers Squibb· Source

• Active, not recruiting

  Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

  NCT06608927· Phase 3· Arcus Biosciences, Inc.· Source

• Completed

  FOCALFLEX (CE Mark) Study

  NCT06271967· Abbott Medical Devices· Source

• Completed

  A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of PLN-74809 (bexotegrast) for the treatment of idiopathic pulmonary fibrosis (BEACON-IPF)

  2023-506185-31-00· Phase 2/3· Pliant Therapeutics Inc.· Source

• Active, not recruiting

  Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)

  NCT05853575· Phase 2· Mirati Therapeutics Inc.· Source

• Completed

  Individualized anti-platelet therapy in patients with stable coronary artery disease undergoing stenting

  NCT05773989· Phase 4· St Antonius Hospital· Source

• Terminated

  Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis

  NCT06097260· Phase 2· Pliant Therapeutics, Inc.· Source

• Completed

  Routine Versus Selective Protamine Administration to Reduce Bleeding Complications After Transcatheter Aortic Valve Implantation (POPular ACE TAVI)

  NCT05774691· Phase 4· St. Antonius Hospital· Source

• Completed

  A study of efficacy and safety of various treatments in participants with idiopathic pulmonary fibrosis (IPF)

  2023-508729-28-00· Phase 2· Novartis Pharma AG· Source

• Completed

  The Effectiveness of Adding Braun Anastomosis to Standard Child Reconstruction After Pancreatoduodenectomy

  NCT05709197· Radboud University Medical Center· Source

• Completed

  Upper Extremity Versus Lower Extremity Accessory Access Sites During Transcatheter Aortic Valve Implantation

  NCT05672823· Radboud University Medical Center· Source

• Completed

  Pulsed Field Ablation and Pulsed Field CRyoAbLation in PErsistent AtriaL FibrilLation

  NCT05408754· Adagio Medical· Source

• Active, not recruiting

  A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer

  NCT05565378· Phase 2· GlaxoSmithKline· Source

• Completed

  A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

  NCT05321069· Phase 3· Boehringer Ingelheim· Source

• Completed

  Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis

  NCT05415137· Phase 3· aTyr Pharma, Inc.· Source

• Active, not recruiting

  A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab

  NCT05142696· Phase 1/2· Novartis Pharmaceuticals· Source

• Terminated

  Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia

  NCT05079230· Phase 3· Gilead Sciences· Source

• Terminated

  iCLAS™ Cryoablation System Post-Market Clinical Follow-up (PMCF) Study

  NCT05416086· Adagio Medical· Source

• Completed

  Access to Pirfenidone Solution for Inhalation (AP01) for Treatment of Progressive, Fibrosing Interstitial Lung Diseases, including Idiopathic Pulmonary Fibrosis

  2024-515964-30-00· Phase 2· Avalyn Pharma Inc.· Source

• Active, not recruiting

  Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)

  NCT04793958· Phase 3· Mirati Therapeutics Inc.· Source

• Recruiting

  WE-TRUST (Workflow Optimization to Reduce Time to Endovascular Reperfusion for Ultra-fast Stroke Treatment)

  NCT04701684· Philips Clinical & Medical Affairs Global· Source

• Completed

  Cryoablation for Monomorphic Ventricular Tachycardia (CryoCure-VT)

  NCT04893317· Adagio Medical· Source

• Completed

  Cardionomic STOP-ADHF Study

  NCT04814134· Cardionomic Inc.· Source

• Active, not recruiting

  Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation

  NCT04685135· Phase 3· Mirati Therapeutics Inc.· Source

• Completed

  Periprocedural Continuation Versus Interruption of Oral Anticoagulant Drugs During Transcatheter Aortic Valve Implantation (POPular PAUSE TAVI)

  NCT04437303· Phase 4· St. Antonius Hospital· Source

• Completed

  Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-Small Cell Lung Cancer

  NCT04475939· Phase 3· GlaxoSmithKline· Source

• Recruiting

  Abbott Vascular Medical Device Registry

  NCT04573660· Abbott Medical Devices· Source

• Completed

  Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson's Disease

  NCT04379050· Phase 3· AbbVie· Source

• Terminated

  ACT Guided Heparinization During Open Abdominal Aortic Aneurysm Repair.

  NCT04061798· Phase 4· Dijklander Ziekenhuis· Source

• Completed

  iCLAS™ for Persistent Atrial Fibrillation

  NCT04061603· Adagio Medical· Source

• Completed

  Comparison of Anticoagulation With Left Atrial Appendage Closure After AF Ablation

  NCT03795298· Boston Scientific Corporation· Source

• Completed

  Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011)

  NCT03898180· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  POLESTAR Trial - An International Multi-center Early Discharge TAVI Program

  NCT03910751· Erasmus Medical Center· Source

• Completed

  Non-interventional Study of Ocrelizumab in Participants With Relapsing or Primary Progressive Multiple Sclerosis

  NCT03593590· Hoffmann-La Roche· Source

• Completed

  The TransCatheter Valve and Vessels Trial

  NCT03424941· Maatschap Cardiologie Zwolle· Source

• Completed

  Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer

  NCT03511664· Phase 3· Endocyte· Source

• Completed

  Nivolumab Combined With Daratumumab With or Without Low-dose Cyclophosphamide

  NCT03184194· Phase 2· Amsterdam UMC, location VUmc· Source

• Terminated

  Improved Prediction of Recurrent Stroke and Detection of Small Volume Stroke

  NCT04019483· UMC Utrecht· Source

• Completed

  PROMISE International

  NCT03321552· LimFlow SA· Source

• Terminated

  Assessment of the WATCHMAN™ Device in Patients Unsuitable for Oral Anticoagulation

  NCT02928497· Boston Scientific Corporation· Source

• Completed

  AMPLATZER™ Amulet™ LAA Occluder Trial

  NCT02879448· Abbott Medical Devices· Source

• Completed

  Combined Endoscopic Epicardial and Percutaneous Endocardial Ablation Versus Repeated Catheter Ablation in Persistent and Longstanding Persistent Atrial Fibrillation

  NCT02695277· AtriCure, Inc.· Source

• Completed

  Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]

  NCT02486718· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)

  NCT02257736· Phase 3· Aragon Pharmaceuticals, Inc.· Source

• Completed

  A Study of LY2875358 in Participants With Non-Small Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations

  NCT01897480· Phase 2· Eli Lilly and Company· Source

• Completed

  ANCHOR (Aneurysm Treatment Using the Heli-FX™ EndoAnchor™ System Global Registry)

  NCT01534819· Medtronic Cardiovascular· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Sarcoidosis14 works · 1 trial
• Barrett's oesophagus10 works · 3 trials